Gastrointestinal & Mucosal Integrity BPC-157 has also been studied for its influence on gut and mucosal tissue
Treatment options include lifestyle changes, dietary adjustments, and, in some cases, supplementation
Consult a skincare professional before starting any new skincare routine.
Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling
Tesamorelin vs CJC-1295/Ipamorelin at a Glance Tesamorelin FDA Status FDA-approved (Egrifta, November 2010) CJC-1295/Ipam FDA Status Compounded (CJC-1295 reached Phase 2) Tesamorelin Mechanism GHRH receptor only (DPP-IV protected) CJC-1295/Ipam Mechanism GHRH + ghrelin receptor (dual pathway) Strongest Evidence Tesamorelin: 2 Phase 3 RCTs, 816 patients, CT-measured fat Most Popular CJC-1295/Ipamorelin (dual pathway, broader benefits) The Core Difference Tesamorelin and CJC-1295 both bind the GHRH receptor on pituitary somatotroph cells to stimulate growth hormone release
